A Single Arm, Open Label, Phase II, Multicenter Study to Assess The Detection of The BRAF V600 Mutation on cfDNA From Plasma in Patients With Advanced Melanoma
Phase of Trial: Phase II
Latest Information Update: 17 Oct 2017
At a glance
- Drugs Cobimetinib (Primary) ; Vemurafenib (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- Acronyms COBIRAF
- Sponsors Roche
- 01 Aug 2017 Planned End Date changed from 28 May 2021 to 28 Jul 2021.
- 01 Aug 2017 Planned primary completion date changed from 28 May 2021 to 31 Dec 2017.
- 10 Jun 2017 Biomarkers information updated